Drugs / MenACWY
MenACWY
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04324606 | Apr 2020 → Feb 2025 | Coronaviridae infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT04056117 | Sep 2019 → Sep 2022 | shigellosis | LimmaTech Biologics AG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06523231 | Apr → Aug 2025 | shigellosis | LimmaTech Biologics AG | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02106390 | Jun 2014 → Oct 2016 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02446691 | Jul 2015 → Dec 2017 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05919472 | Jul 2023 → Jul 2024 | iron deficiency anemia | Nicole Stoffel | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT06213506 Comparator | Jan 2024 → Sep 2026 overdue | salmonellosis | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03929757 Background | Aug 2019 → Aug 2022 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03433482 Comparator | Aug 2018 → Jul 2019 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03587207 Comparator | Jul → Dec 2018 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02140762 Comparator | May → Nov 2014 | meningococcal infection | Novartis Vaccines | Completed | Met primary |
| Phase 3 | NCT04536051 Comparator | Jun 2020 → Sep 2021 | COVID-19 | University of Oxford | Unknown | Met primary |
| Phase 3 | NCT03165617 Comparator | May 2017 → Sep 2019 | influenza | Seqirus | Completed | Met primary |
| Phase 3 | NCT02509494 Comparator | Sep 2015 → Jun 2019 | Ebola hemorrhagic fever | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | GlaxoSmithKline | GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission gsk.com ↗ |
| 2024-09-24 | GlaxoSmithKline | GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion gsk.com ↗ |
| 2022-10-17 | GlaxoSmithKline | US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W gsk.com ↗ |
| 2011-03-02 | GlaxoSmithKline | Regulatory update: Nimenrix® (MenACWY vaccine) gsk.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY | “The comparator was (meningococcal [Groups A, C, W-135, and Y] oligosaccharide diphtheria CRM197 conjugate vaccine [Men ACWY]).” NCT03165617 ↗ |
| Known as | Meningococcal ACWY Conjugate Vaccine | “Meningococcal ACWY Conjugate Vaccine, MenACWY” NCT02106390 ↗ |
| Known as | Menveo | “meningococcal serogroup A, C, W-135, and Y (Menveo®, GlaxoSmithKline Biologicals, S.A.)” NCT03165617 ↗1“MenACWY (Menveo) vaccine” NCT03587207 ↗ |
| Modality | Vaccine | “Meningococcal ACWY Conjugate Vaccine, MenACWY” NCT02106390 ↗ |
| Route | Intramuscular | “0.5 mL MenACWY vaccine (IM)” NCT02140762 ↗ |